Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr Mouabbi on Clinical Trials for Invasive Lobular Breast Cancer

July 23rd 2024

Jason A. Mouabbi, MD, discusses clinical trials aimed at expanding the treatment paradigm for invasive lobular breast cancer.

DESTINY-Breast03 and DESTINY-Breast06 Data Shape Metastatic Breast Cancer Treatment

July 23rd 2024

Paolo Tarantino MD, and V. K. Gadi, MD, PhD discuss data from DESTINY-Breast03 and DESTINY-Breast06.

Enhanced Clinical Education and Simplified Guidelines Needed to Address Germline Testing Gaps in Breast Cancer

July 22nd 2024

Sonya Reid, MD, MPH, discusses barriers to universal germline testing utilization in breast cancer, particularly among underserved populations.

Research With ctDNA Continues to Pave the Way Toward Optimal Breast Cancer Management

July 22nd 2024

Circulating tumor DNA is in constant flux, rendering its evaluation potentially useful in metastatic breast cancer management.

V. Craig Jordan, PhD, the ‘Father of Tamoxifen,’ Dies at 76

July 22nd 2024

V. Craig Jordan, PhD, of The University of Texas MD Anderson Cancer Center and a pioneer in the field of breast cancer, died on June 9, 2024.

Combinations and Treatment Sequence Strategies in Breast Cancer

July 22nd 2024

In their discussion, the key opinion leaders explore the potential of combination therapies in HR+/HER2- metastatic breast cancer, with a specific focus on the ELECTRA study, which investigated the combination of elacestrant and abemaciclib.

PostMONARCH: Dissecting Data on Sequential CDK 4/6 Inhibitors

July 22nd 2024

The expert panel examines the subgroup data from the postMONARCH study, focusing on patients with ESR1 and PIK3CA mutations, and emphasizes the important role of CDK4/6 inhibitors in the treatment of these specific patient populations with HR+/HER2- metastatic breast cancer.

Dr Gandhi on Considerations for Continuing CDK4/6 Inhibitors After Progression in HR+ Advanced Breast Cancer

July 22nd 2024

Shipra Gandhi, MD, discusses considerations for continuing with a CDK4/6 inhibitor or switching therapies in HER2- negative advanced breast cancer.

FDA Grants Fast Track Designation to HP518 for AR+ TNBC

July 22nd 2024

The FDA has granted fast track designation to HP518 for androgen receptor–positive triple-negative breast cancer.

Clinical Perspectives on Managing ILD Related to T-DXd

July 22nd 2024

Breast cancer specialists discuss adverse events associated with T-DXd, focusing on monitoring for interstitial lung disease (ILD) and the role of re-challenging patients with T-DXd after resolution of grade 1 ILD.

Overview of DESTINY-Breast06

July 22nd 2024

Aditya Bardia, MD, MPH, shares comprehensive insights on the DESTINY-Breast06 study evaluating T-DXd in HER2-low and HER2 ultra-low metastatic breast cancer, and the panel offers its initial impressions.

Dr Feldman on New Approaches for Decreasing the Risk of Breast Cancer–Related Lymphedema

July 20th 2024

Sheldon Feldman, MD discusses new approaches for decreasing the risk of and managing breast cancer¬–related lymphedema.

Dr Mukhtar on Challenges in the Diagnosis and Management of Invasive Lobular Carcinoma

July 20th 2024

Rita Mukhtar, MD, discusses challenges in the diagnosis and management of invasive lobular carcinoma.

Dr Pusztai on Molecular Residual Disease Monitoring in Early Breast Cancer

July 20th 2024

Lajos Pusztai, MD, DPhil, discusses the progress and challenges in monitoring molecular residual disease in early breast cancer.

AE Management and Prevention Strategies for ADCs, Immunotherapy in Breast Cancer

July 19th 2024

Hope Rugo, MD, discusses the management of treatment-limiting toxicities in breast cancer, including the use of antibody-drug conjugates and immunotherapy.

Dr Rugo on Managing Treatment-Limiting Toxicities in Breast Cancer

July 19th 2024

Hope S. Rugo, MD discusses managing treatment-related toxicities within the scope of the current breast cancer treatment paradigm.

Dr Davis on the Utility of ADCs in Breast Cancer

July 18th 2024

Andrew Davis, MD, discusses the use of antibody-drug conjugates in breast cancer, highlighting recent updates with these agents in the treatment paradigm.

Dr Waks on Key Questions Regarding the First-Line Use of T-DXd in HER2+ Breast Cancer

July 17th 2024

Adrienne G. Waks, MD, discusses implications of the potential use of first-line T-DXd in HER2-positive breast cancer.

Emerging Trials in the Management of HR+/HER2- Locally Advanced or Metastatic Breast Cancer

July 16th 2024

Adam M. Brufsky, MD, PhD, and Erika P. Hamilton, MD, share their perspectives on the future landscape of HR+/HER2- locally advanced or metastatic breast cancer treatment and provide essential insights to summarize the key points of their discussion.

Adverse Event Monitoring and Management in HR+/HER2- Locally Advanced and Metastatic Breast Cancer

July 16th 2024

Medical experts address the challenges of managing adverse events in the treatment of HR+/HER2- locally advanced or metastatic breast cancer.